Market capitalization | $1.06b |
Enterprise Value | $817.97m |
P/E (TTM) P/E ratio | 28.00 |
EV/FCF (TTM) EV/FCF | 12.78 |
EV/Sales (TTM) EV/Sales | 3.31 |
P/S ratio (TTM) P/S ratio | 4.28 |
P/B ratio (TTM) P/B ratio | 3.08 |
Revenue growth (TTM) Revenue growth | 29.20% |
Revenue (TTM) Revenue | $247.30m |
As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.
6 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:
6 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:
Mar '25 |
+/-
%
|
||
Revenue | 247 247 |
29%
29%
|
|
Gross Profit | 218 218 |
28%
28%
|
|
EBITDA | 68 68 |
228%
228%
|
EBIT (Operating Income) EBIT | 48 48 |
170%
170%
|
Net Profit | 40 40 |
164%
164%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
Head office | Canada |
CEO | Peter Greenleaf |
Employees | 130 |
Founded | 1993 |
Website | www.auriniapharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.